key: cord-0842399-95sojsli
authors: Busnadiego, I.; Abela, I. A.; Frey, P. M.; Hofmaenner, D. A.; Scheier, T. C.; Schuepbach, R. A.; Buehler, P. K.; Brugger, S. D.; Hale, B. G.
title: Herpesvirus Reactivations in Critically-Ill COVID-19 Patients with Autoantibodies Neutralizing Type I Interferons
date: 2022-03-21
journal: nan
DOI: 10.1101/2022.03.19.22272532
sha: 6599046ff144a10093bfd1ff6324507388461c73
doc_id: 842399
cord_uid: 95sojsli

Autoantibodies neutralizing the antiviral action of type I interferons (IFNs) have been associated with pre-disposition to severe COVID-19. Here, we screened for such autoantibodies in 103 critically-ill COVID-19 patients in a tertiary intensive care unit in Switzerland. Eleven patients (10.7%), but no healthy donors, had neutralizing anti-IFN or anti-IFN/anti-IFN{omega} IgG in plasma/serum, but anti-IFN IgM or IgA was rare. One patient had non-neutralizing anti-IFN IgG. Strikingly, all patients with plasma anti-IFN IgG also had anti-IFN IgG in tracheobronchial secretions, identifying these autoantibodies at anatomical sites relevant for SARS-CoV-2 infection. Longitudinal analyses revealed patient heterogeneity in terms of increasing, decreasing, or stable anti-IFN IgG levels throughout the length of hospitalization. Notably, presence of anti-IFN autoantibodies in this critically-ill COVID-19 cohort appeared to predict herpesvirus (herpes simplex viruses types 1 and 2, HSV-1/-2; and/or cytomegalovirus, CMV) reactivations, which are linked to worse clinical outcomes. Indeed, all seven tested COVID-19 patients with anti-IFN IgG in our cohort (100%) suffered from one or more herpesvirus reactivations, and analysis revealed that these patients were substantially more likely to experience CMV reactivation than COVID-19 patients without anti-IFN autoantibodies, even when adjusting for systemic steroid treatment (odds ratio 7.28, 95%-CI 1.14-46.31, p=0.036). As the IFN system deficiency caused by neutralizing anti-IFN autoantibodies likely directly and indirectly exacerbates herpesvirus reactivations in critically-ill patients, early diagnosis of anti-IFN IgG could be rapidly used to inform risk-group stratification and treatment options.

4 immune cell dysfunction [2, [5] [6] [7] [8] 10 ]. These functional consequences likely permit higher 7 dilution in PBS/BSA (Southern Biotech: IgA 205009; IgM 202009; IgG 204009; mouse to the MFI obtained from albumin-coated beads. For each isotype, the mean and 147 standard deviations (SDs) were calculated from the MFI values obtained from the 148 healthy donor samples, and MFI values above 10 SDs for IFNα2, or 5 SDs for IFNω 149 were considered positive. 150

In validation experiments, the mouse monoclonal IgG antibody targeting human IFNα2 152 (clone ST29) exhibited specific reactivity to beads coated with human IFNα2 (as 153 compared to beads coated with albumin), but showed some cross-reactivity to beads 154 coated with human IFNω, and no cross-reactivity to beads coated with human IFNβ 155 Figure 1B) . Similarly, the mouse monoclonal IgG antibody targeting 156 human IFNβ (clone MMHB-15) was highly specific to beads coated with human IFNβ, 157 and gave no reactivity to beads coated with IFNα2, but showed some cross-reactivity to 158 beads coated with human IFNω (Supplementary Figure 1C) . The mouse monoclonal 159

IgG antibody targeting human IFNω (clone 04) was highly specific to beads coated with 160 human IFNω, and gave no reactivity to beads coated with either IFNα2 or IFNβ 161 (Supplementary Figure 1D) . When the assay was validated with human samples, 162 pooled sera from a panel of 20 healthy donors exhibited no IgG binding to either IFNα2 163 or IFNβ beads, but some low reactivity to IFNω beads (Supplementary Figure 1E, left  164 panel). The human polyclonal anti-IFNα2b antiserum had IgG that strongly reacted with 165 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 21, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 IFNα2 and IFNω is expected given the close relatedness of these type I IFNs and 168 previous descriptions of cross-reactive monoclonal antibodies [2, 18] . intensity of control wells that had not been stimulated with either IFNα2 or IFNω. 188 189 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) females, aged 19-69) were used as a negative control group to set benchmark 206 thresholds. We observed that 11.3% (9/80) of male severe COVID-19 patients and 207 13.0% (3/23) of female severe COVID-19 patients had clearly detectable IgG 208 autoantibodies targeting IFNα2 in their plasma, which were not present in the plasma of 209 130 healthy donors ( Figure 1A) . Anti-IFNα2 autoantibodies were largely confined to the 210 IgG class, as few individuals had IgA or IgM reactivity to IFNα2, although one male 211 COVID-19 patient was highly positive for anti-IFNα2 IgM ( Figure 1A) . We similarly 212 detected prevalent reactivity of autoantibodies against IFNω, with detectable IgG 213 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) the anti-IFNα2 IgG positive samples (7 patients) were negative for anti-IFNω IgG. While 219

IgA autoantibodies targeting IFNω were observed in a few individuals (6/80 males and 220 2/23 females), it was striking that 5% (4/80) of males were positive for anti-IFNω IgM, 221 which could be suggestive of recent induction of these anti-IFNω antibodies ( Figure  222 1B). The identification of anti-IFN autoantibodies in ~10% of severe COVID-19 patients 223 is fully in-line with previous reports from others [2] [3] [4] [5] [6] [7] . 224 225

Ill COVID-19 Patients. In order to have direct functional consequences for SARS-CoV-2 227 replication, autoantibodies targeting type I IFNs would have to be present in either the 228 nasopharynges or tracheal tracts, as recently demonstrated [8, 9] . We therefore used our 229 antibody binding assay to assess anti-IFNα2 and anti-IFNω IgG, IgA and IgM 230 autoantibodies in tracheobronchial secretions obtained from 88 of the severe COVID-19 231 patients in our cohort. Stratifying by plasma IgG positivity to either IFNα2 or IFNω, it was 232 clear that patients with detectable plasma IgG to type I IFNs (particularly IFNα2) also 233 had detectable anti-IFN IgG autoantibodies in their tracheobronchial secretions ( Figures  234   1C & D) . In contrast, we did not readily detect either IgA or IgM anti-IFN autoantibodies 235 in tracheobronchial secretions. Assessment of anti-IFNβ autoantibody levels did not 236 reveal differences between severe COVID-19 patients who were positive or negative for 237 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (Figures 2A and B) . A recent report has also noted 251 either stable or fluctuating levels of anti-IFNα2 IgG autoantibodies following hospital 252 admission for . Given our lack of 'baseline' samples from individuals prior 253 to their infection with SARS-CoV-2, and the fact that our earliest samples are from 254 admittance to ICU (likely a late event in disease progression), it is impossible to 255 conclude whether these anti-IFN autoantibodies pre-existed in these individuals prior to 256 COVID-19. However, the general lack of anti-IFN IgM autoantibodies in most individuals, 257 even at these relatively late times, may be suggestive that the autoantibodies pre-258 existed. 259 260 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 21, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 adapted a standard cell-based luciferase reporter assay that relies on IFN-stimulated 263 activation of the IFN-inducible Mx1 promoter ( Figure 2C) . Notably, 21/23 patient 264 plasmas with detectable anti-IFNα2 IgG autoantibodies were able to neutralize the 265 function of IFNα2 in this assay, irrespective of whether a low concentration of IFNα2 (0.2 266 ng/mL) or a high concentration of IFNα2 (10 ng/mL) was used ( Figure 2D ). Strikingly, 267 2/23 patient plasmas (both originating from patient 37, a female in her 70s) did not 268 exhibit neutralization capabilities at any of the IFNα2 concentrations tested, despite 269 having higher IFNα2-binding IgG titers than many other samples that did neutralize 270 IFNα2 ( Figure 2D ). Similar data were obtained when neutralization of IFNω was 271 assessed, although differences were noted ( Figure 2D ). For example, some samples 272 from patient 19 (a male in his 60s) and patient 31 (a male in his 50s) did not have 273 detectable anti-IFNω-binding IgG autoantibodies, though they could efficiently neutralize 274 low IFNω concentrations (0.2 and 1 ng/mL), but not high IFNω concentrations (10 275 ng/mL), possibly due to cross-reactive anti-IFNα2-binding antibodies present in the 276 samples or differences in sensitivity between the binding and neutralization assays. 277 278

Reactivation. We assessed links between having anti-IFN autoantibodies and several 280 patient characteristics associated with worse clinical outcomes in COVID-19 patients 281 admitted to ICU. In the context of patient baseline characteristics, we could not observe 282 any attributes that correlated with the presence of anti-IFNα IgG autoantibodies, 283

including age, gender, body mass index or several chronic underlying conditions, such 284 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 21, 2022. ; https://doi.org/10. 1101 /2022 were unable to observe any clear association between presence of anti-IFN 286 autoantibodies and outcomes such as death, length of hospitalization, length of ICU 287 stay, or duration of ventilation ( Table 2) . We therefore assessed more quantifiable 288 parameters that can impact disease outcomes in ICU, such as the prevalence of 289 bacterial superinfections in the blood or respiratory tract, and the reactivation of 290 herpesviruses such as HSV-1/2, CMV and VZV in the blood. While we were unable to 291 find an association between presence of anti-IFN autoantibodies and the likelihood of 292 bacterial superinfections ( Figure  294 3). Specifically, in our cohort of 103 patients, a subset of 59 (57%) were tested for HSV-295 1/2, VZV or CMV reactivation according to the clinical situation. Of these 59 patients, 296

herpesvirus reactivations were observed in 38 (64%) patients, consisting of 30 (51%) 297 patients with HSV-1/2, 21 (36%) with CMV, and none with VZV (Table 3) . Thirteen 298 (22%) of the 59 patients had both HSV-1/2 and CMV reactivations. Strikingly, all patients 299 in this subset of patients with anti-IFN autoantibodies (n=7, 100%) experienced a 300 herpesvirus reactivation event, although not all patients with reactivation also had anti-301 IFN autoantibodies ( herpesviruses. Anti-IFN autoantibodies were not detected in any of the healthy donors 319 tested, suggesting an enrichment in critically-ill COVID-19 patients that may contribute to 320 the development of severe disease in some individuals. However, we note that (at least 321 within our rather small COVID-19 ICU cohort), presence of anti-IFN autoantibodies was 322 not associated with parameters such as death, length of hospitalization, length of ICU 323 stay, or duration of ventilation. While this broadly contrasts with the findings of others 324 who noted an association between presence of anti-IFN autoantibodies and increased 325 COVID-19 disease severity parameters [2, 3, 5, 7] , this difference could be explained by a 326 lack of power in our exploratory study or masking effects of the high standard of care in 327 a high-resource setting. Nevertheless, the proportion of critically-ill COVID-19 patients in 328 our cohort with anti-IFN autoantibodies is remarkably consistent with the findings from 329 several independent severe COVID-19 cohorts recently studied across Europe and 330

North America, despite the use of different detection assays [2] [3] [4] [5] [6] [7] 19, 20] . Indeed, in the 331 future, it will probably be important to have standardized quantitative assays and 332 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 21, 2022. ; https://doi.org/10. 1101 /2022 mean that their presence is under-or over-estimated. In particular, it was shown that 334 assaying IFN neutralization, rather than simply binding, increases the detection of 335 functionally relevant anti-IFN autoantibodies because such assays are likely to be 336 sensitive to much lower, potentially more physiologically-relevant, concentrations of IFNs 337 reactivations in humans have also been reported following treatment regimens involving 376 tofacitinib or baricitinib (two JAK inhibitors that limit functionality of the IFN system) 377 [28, 29] . Furthermore, and most importantly perhaps, a recent study of individuals 378 suffering from autoimmune polyendocrine syndrome type I (APS-1; a genetic disease 379 caused by defects in the AIRE gene leading to production of autoantibodies targeting 380 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 21, 2022. A clear limitation of our study is the low patient sample size in our cohort and single-389 center study design, that did not provide us with sufficient statistical power to allow 390 detection of small differences in clinical outcomes. This could be improved in future 391 studies with higher participant numbers, and in studies with a pre-defined systematic 392 sampling procedure for the detection of herpesvirus reactivations. Moreover, studies 393 should perhaps investigate associations between the amount of reactivated herpesvirus 394 load, the magnitude of IFN system suppression by anti-IFN autoantibodies, 395 immunomodulation induced by clinicians, and multiple relevant patient outcomes (e.g. 396 length of stay in ICU, length of stay in hospital, duration of mechanical ventilation, 397 duration of ARDS, and mortality). We also acknowledge that our study is limited by the 398 inability to assess levels of anti-IFN autoantibodies in patients prior to SARS-CoV-2 399 infection. Thus, we can currently only speculate that an immunodeficient state was pre-400 existing in certain patients and exacerbated COVID-19 severity and the likelihood of 401 herpesvirus reactivations. 402 403 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 21, 2022. ;  type I IFNs can be performed relatively easily and rapidly, and could be used in future 405 diagnostic efforts to understand the underlying causes of severe disease in both COVID-406 19 and other infectious disease manifestations [32] . While there are currently no specific 407 therapies available to counteract the potentially pathogenic activities of anti-IFN 408 autoantibodies, their early diagnosis could be used to stratify 'at-risk' individuals for 409

prophylactic vaccinations, or particular drug regimens following infections with certain 410 pathogens, although further evidence would be required to assess benefits of such a 411 strategy. Furthermore, as described here, rapid detection of anti-IFN autoantibodies in 412

ICUs may have diagnostic value in assessing predisposition to potentially detrimental 413 herpesvirus reactivations, and thus in prescribing prophylactic therapeutic options to limit 414 their contributions to severe disease. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 21, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 21, 2022. ;  plasma anti-IFNα2 IgG. Samples were collected on day of admission to ICU (d1) and as 453 indicated thereafter. MFI FC of signal derived from IFN-coated beads relative to the MFI 454 each isotype in Figure 1A , and are used as threshold values for positivity (filled circles). is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 21, 2022. ; HSV-1/2, and CMV and/or HSV-1/2 were used to stratify the results obtained when 477 plasma samples from the same patient were assayed for IgG autoantibodies (autoAbs) 478 targeting IFNα2 (see Figure 1) 515  516  517  518  519  520  521  522  523  524  525  526  527  528  529  530  531  532 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 21, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 23 TABLES . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) (31) HSV-1/2 reactivation 30 (51) 6 (86) 24 (46) VZV reactivation 0 --. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 21, 2022. ; https://doi.org/10.1101/2022.03.19.22272532 doi: medRxiv preprint . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 21, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 Neg Pos CMV and/or HSV-1/2 reactivation anti-IFNα2 IgG autoAbs in plasma . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 21, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 

Autoantibodies neutralizing type I IFNs are present in 540 ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-541 19 deaths

Neutralizing Autoantibodies to Type I IFNs in >10% of 543 Patients with Severe COVID-19 Pneumonia

Autoantibodies against type I interferons are associated 546 with multi-organ failure in COVID-19 patients

2021) Type I interferon autoantibodies are associated 551 with systemic immune alterations in patients with COVID-19

Early nasal type I IFN immunity against SARS-CoV-2 is 554 compromised in patients with autoantibodies against type I IFNs. The Journal of 555 experimental medicine 218

HSV-1 reactivation is associated with an increased risk of 565 mortality and pneumonia in critically ill COVID-19 patients

Reversible silencing of cytomegalovirus genomes by type I 568 interferon governs virus latency

Interferon gamma regulates acute and latent murine 571 cytomegalovirus infection and chronic disease of the great vessels. The Journal 572 of experimental medicine

Bacterial pulmonary superinfections are

Multifactorial seroprofiling dissects the contribution of pre-580 existing human coronaviruses responses to SARS-CoV-2 immunity

AIRE-Deficient Patients Harbor Unique High-Affinity 586

Neutralizing Autoantibodies to Type I Interferons in

Antibodies against type I interferon: detection and 592 association with severe clinical outcome in COVID-19 patients

Cytomegalovirus reactivation in immunocompetent 595 mechanical ventilation patients: a prospective observational study

Characteristics and prognosis of Herpesviridae-related 598 pneumonia in critically ill burn patients

Reactivation of multiple viruses in patients with sepsis

Cytomegalovirus reactivation in critically ill 602 immunocompetent patients

Safety of Tofacitinib in a Real-World Cohort of Patients 611

Herpes simplex infection in a patient with 614 rheumatoid arthritis treated with baricitinib: a case report

Patients with autoimmune polyendocrine syndrome type 617 1 have an increased susceptibility to severe herpesvirus infections

Primary and Acquired Immunodeficiencies Associated 620

With Severe Varicella-Zoster Virus Infections

Auto-antibodies to type I IFNs can underlie adverse 623 reactions to yellow fever live attenuated vaccine. The Journal of experimental 624 medicine 218